Serbia presses on with US, Russia talks to lift sanctions threat on NIS oil company, minister says-February 2024-www.financetom.com

Serbia presses on with US, Russia talks to lift sanctions threat on NIS oil company, minister says

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Serbia presses on with US, Russia talks to lift sanctions threat on NIS oil company, minister says

Feb 25, 2025 11:39 PM

BELGRADE, Feb 26 (Reuters) - Serbia is pressing on with

talks with the United States and Russia in a bid to avoid

threatened U.S. sanctions on Serbian oil company NIS, energy

minister Dubravka Djedovic Handanovic said on Wednesday.

(Reporting by Aleksandar Vasovic; Editing by)

Previous page： Russia will prepare an export restrictions list in the near future, Interfax cites deputy PM Next page： ANI Pharmaceuticals Says FDA Approved Generic Version of Nizoral Anti-Dandruff Shampoo

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Russia will prepare an export restrictions list in the near future, Interfax cites deputy PM

Sep 28, 2024

MOSCOW, Sept 26 (Reuters) - Russia will prepare a list of export restrictions that will include minerals and refined products in the near future, the Interfax news agency reported on Thursday, citing Deputy Prime Minister Alexander Novak. ...

ANI Pharmaceuticals Says FDA Approved Generic Version of Nizoral Anti-Dandruff Shampoo

Sep 28, 2024

08:28 AM EDT, 09/26/2024 (MT Newswires) -- ANI Pharmaceuticals ( ANIP ) said Thursday that the US Food and Drug Administration has approved the Abbreviated New Drug Application for its Ketoconazole shampoo, 2%, a generic version of the Nizoral anti-dandruff shampoo. The company also said it has commercially launched the product. Shares of the company were up 3.6% in recent...

AbbVie's Parkinson's Disease drug meets main goal in late-stage trial

Sep 28, 2024

Sept 26 (Reuters) - AbbVie ( ABBV ) said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease. (Reporting by Sriparna Roy in Bengaluru; Editing by Anil D'Silva) ...

Pfizer withdraws sickle cell disease treatment on risk of complication, death

Sep 28, 2024

Sept 26 (Reuters) - U.S. drugmaker Pfizer ( PFE ) said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths. Pfizer ( PFE ) bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022....